Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07770815 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07770815 · ClinicalTrials.gov record · last posted 2026-08-18

Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)

Name: Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) — clinical trial record (NCT07770815)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.

Started2026-09-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric participants aged 2 to 17 years with IgA nephropathy (IgAN). Sibeprenlimab will be administered as an add-on to standard of care therapy consisting of angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs).

Trial Details

NCT Number	NCT07770815
Lead Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions	IgA Nephropathy
Enrollment	24 participants
Start Date	2026-09-30
Primary Completion	2029-12-29 (estimated)
Study Completion	2030-02-23 (estimated)
Updated on ClinicalTrials.gov	2026-08-18